Toremifene
Also known as: Fareston, Toremifene citrate, FC-1157a
Classification
Serm
Regulatory Status
FDA-approved prescription product
Sources
8
Review
n/a
Overview
Toremifene is a triphenylethylene SERM that competes with estrogen for receptor binding in breast tumor tissue (primarily antiestrogenic antitumor effect) while showing estrogen-agonist activity in some other tissues such as bone.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
antiestrogenic effect in breast tumor tissue
Benefits
FDA-approved (Fareston, toremifene citrate) for metastatic breast cancer in postmenopausal women with ER-positive or unknown tumors; educational reference only.
Interactions & cautions
Drug interactions
drugs known to prolong the QT interval — Increased arrhythmia risk including Torsade de pointes (high)
strong CYP3A4 inhibitors — May increase QT and other concentration-related toxicity (high)
strong CYP3A4 inducers — Possible reduced efficacy (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw